Attention Deficit Hyperactivity Disorder Therapeutics Market

Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook (2023-2033)

The global revenue from the attention deficit hyperactivity disorder therapeutics market was approximately US$ 21.3 Bn in 2022, with the global market expected to grow at a CAGR of 8.0% to reach a valuation of approximately US$ 49.1 Bn by the end of 2033.

As assessed by Persistence Market Research, stimulants hold a market value of around US$ 18.4 Bn by 2022. Overall, attention deficit hyperactivity disorder therapeutics market sales account for approximately 26.9% revenue share in the global neurological disorder drugs market, which was valued at around US$ 79.4 Bn in 2022.

Sales Analysis of Market from 2015 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 5.3% in the last 7 years from 2015 to 2022.

Attention deficit hyperactivity disorder (ADHD) is a neurobiological behavioural disease that affects children, adolescents, and adults. It is characterised by issues with focus, hyperactivity, and impulsivity and is brought on by an imbalance of the chemical neurotransmitters dopamine and noradrenaline in the brain. Methylphenidate and amphetamines are examples of psychostimulant first-line treatments for ADHD. Atomoxetine is an example of a non-psychostimulant first-line medication.

In order to be diagnosed with ADHD, a person must have both functional limitations across numerous contexts and symptoms of inattention, hyperactivity, and/or impulsivity that are developmentally inappropriate. Academic performance, peer interactions, and family functioning are among the functional areas that ADHD affects. The main justification for clinical referral is typically functional limitations rather than newly appearing symptoms.

According to a systematic review and meta-analysis published in Neuroscience & Biobehavioral Reviews, Volume 99, 2019, the high incidence of ADHD makes it a significant public health issue worldwide. It currently ranks as the most prevalent neuropsychiatric disorder, affecting 5–10% of adolescents and children.

While the majority of research focus on children aged 7 to 17, it is crucial to note that adults can also have ADHD. It has been hypothesised that more adults now suffer with ADHD than there were 20 years ago. A portion of this rise can be attributed to 76% of diagnosed patients still experiencing ADHD symptoms as adults.

ADHD indicates significant difficulties with academic, interpersonal, and professional performance. Numerous environmental factors that occur during various phases of the central nervous system's development, such as the gestational and perinatal periods, are linked to the incidence of ADHD.

Numerous studies have shown that the aetiology of ADHD has a significant genetic component. Numerous genes that have been linked to ADHD are involved in synaptogenesis, neurotransmission, neurogenesis, and receptor placement in synapses, among other activities.

The effectiveness of various treatments for each type of ADHD presentation and stage of development has still not been thoroughly analysed. Given its high incidence and high cost of treatment, ADHD is frequently diagnosed in children and poses a global public health issue, driving demand in the global market.

The global market is thus likely to show high growth over the coming years at a CAGR of 8.0% and reach a global market size of US$ 49.1 Bn by 2033.

How Can the Global Market Grow?

“Establishment of Adjuvant Therapies”

ADHD is currently treated symptomatically with medication, which considerably reduces the primary symptoms. However, medication alone does not often provide adequate relief from both the primary and secondary symptoms of ADHD. Due to side effects, drug treatment anxiety, and ADHD children's and their guardians' adherence to and rejection of drugs, interest in additional non-pharmaceutical treatments that can support drug therapy is rising.

Behaviour therapy is the most common non-drug treatment used for ADHD. Adjuvant therapy known as digital therapy (DTx) has recently been established as a result of the advancement of mobile-based software technologies.

With the help of DTx, it is possible to increase drug adherence, monitor patients without regard to location or time, and facilitate daily communication with patients, all of which can be extremely helpful for long-term psychiatric diseases like ADHD.

Video-based gaming exercise has been efficient for health-related aspects such as movement patterns, cognitive ability, fatigue, and depressed mood. This was found to have nearly the same influence as standard therapies in terms of enhancing the quality of treatment, according to a recent trial looking at the effect on cognitive function as well as other neurological illness symptomatology in patients with multiple sclerosis.

Patients who choose alternative treatments or outcomes free of many pharmacological side effects can benefit from adjuvant therapy employing these digital media.

Additionally, the great accessibility of mobile-based functional games for young children can contribute to an increase in interest in learning about ADHD treatment and active motivation, resulting in enhancements to the therapeutic learning capacity.

The market is expected to expand over the forecasted period as a result of the above-mentioned advances in ADHD therapeutics.

Can the Market Growth Be Affected in Any Way?

“Side-Effects of Pharmacological Therapy, and Limitations of Adjuvant Therapies”

The medications used to treat ADHD have two distinct types of limitations. The first type of concern is that these drugs may have unpleasant side effects like insomnia, lack of appetite, or nausea. But for the majority of people, lowering the dose or switching drugs helps control these side effects.

The second category of issues concerns stimulant drugs, which have addictive elements. Despite the fact that taking stimulant drugs as directed will not cause addiction, they might be misused in a way that does. They may also be transferred to others for either substance abuse or enhanced productivity. This is a particular challenge for stimulants with immediate release.

Additionally, similar to those found for stimulant medication therapy, behavioural interventions for ADHD have limits. For example, compared to their classmates who are usually developing, children with ADHD typically do not exhibit normalised behavioural function when receiving behaviour therapy as a sole form of treatment.

Additionally, some kids do not show progress after a behaviour modification programme. The necessity for ongoing intervention, the complexities of the therapy, the reliance on parental and academic participation, and the comparatively high expense of implementing behavioural therapies relative to pharmacological interventions all contribute to the possibility that using behaviour therapy may be challenging.

Country-wise Insights

Why is the U.S. Market Booming?

“Rising Incidence of Adults with ADHD, and Expansion of the Biopharmaceutical Industry”

The U.S. accounted for around 62.9% share in the global market in 2022.

Drug manufacturers frequently conduct paediatric studies on their products to expand their markets. However, the market is evolving in the opposite direction for medications for attention deficit and hyperactivity disorder (ADHD) that were mainly created with children in mind, with more adults now using the medications than children.

In reality, the growth of the biopharmaceutical industry in the development of novel therapies for ADHD treatment is responsible for the fact that adult Americans are using ADHD medications at a rate that is almost twice as fast as the entire market.

Will Germany Be a Lucrative Market for Attention Deficit Hyperactivity Disorder Therapeutics?

“Rising Focus on Underdiagnosed ADHD in Germany”

Germany held around 2.8% market share of the global market in 2022.

In Germany, both the administrative incidence of adult ADHD diagnoses and the level of adult ADHD medication use have increased recently. This could be seen as a sign that patients and doctors are becoming more aware of the possibilities of adult ADHD. However, compared to the frequency seen in epidemiologic studies, the prevalence of diagnosed ADHD continues to be lower. This would suggest that ADHD is now underdiagnosed and undertreated in adults.

The low incidence of medication use among teenagers with ADHD who are approaching adulthood contributes to the nation's rising demand for ADHD treatments, driving the market's overall growth throughout the forecast period.

How is China Emerging as a Prominent Market?

“Incorporation of ADHD Therapeutics through Regional Expansion”

China held a market share of about 2.5% of the global market in 2022.Growing investments in ADHD research in China, as well as the emergence of market players within the region, are factors promoting the growth of the global market.

In December 2022, Tris Pharma, Inc. and Pediatrix Therapeutics, a pediatrics-focused business that seeks to provide children and families in China with high quality, pediatric-friendly, and affordable therapeutics, announced that they had expanded their partnership. Pediatrix Therapeutics now has the exclusive right to market the entirety of Tris's FDA-approved ADHD portfolio in addition to ADHD pipeline products in China.

These activities are set to promote the stance of China within the global market, over the forecast period.

Category-wise Insights

Which Drug is Driving Demand within the Global Market?

“Stimulants as Greater Preferred Choice of Treatment with Greater Efficacy”

The stimulants segment held around 86.1% share of the total market in 2022.

The most popular class of prescription medication used by doctors to treat ADHD is stimulants. With the most research supporting their efficacy, they have the longest history of treating ADHD. Several commonly used medications fall under the stimulant drug category, including Adderall, Dexedrine, Focalin, and Ritalin.

It is thought that stimulants function by raising dopamine levels in the brain. A neurotransmitter called dopamine is linked to motivation, pleasure, focus, and movement. Stimulant medicines help many ADHD patients concentrate and focus better while lowering hyperactive and impulsive behaviours.

Which Age Group is Largely in Focus within the Global Market?

“Development of Self-Report Scale for Adults Suspecting ADHD”

The adult age group segment holds a share of about 50.7% in 2022.

Adults who have undiagnosed ADHD account for a sizable portion of the global population. A thorough evaluation by a mental health expert is necessary for an adult to receive a diagnosis of ADHD. During this evaluation, the adult will be questioned about their impulsivity, hyperactivity, and attention span. A self-screening test to see whether someone might have adult ADHD has been developed by the World Health Organization.

The Adult Self-Report Scale (ASRS) Screener aids in the identification of adult ADHD symptoms and indications. As a result, this age group segment has become the largest shareholder in the global market due to growing concerns about adults with ADHD.

Which Distribution Channel Offers the Market a Profitable Outlook?

“Rising Patient Pool and Ease of Availability of Prescribed Medications”

Retail pharmacies hold a share of about 44.5% in 2022.

This is due to the ease of access and widespread availability of ADHD medications. The amount of money paid to physicians who frequently treat children and adolescents has increased along with the number of prescriptions written for stimulants, such as those prescribed to manage ADHD in children. The majority of ADHD patients are treated in outpatient settings, which has fueled the segment's expansion.

Patient care programs that provide patients with personal Electronic Health Records (EHRs) to maintain track of their medical history and obtain primary care are also receiving more attention, driving market growth globally.

Competition Landscape

Manufacturers hope to expand their respective market shares by developing novel ADHD drugs at reduced prices.

To cut their manufacturing costs and compete in the market with lower pricing, the corporations are concentrating on outsourcing the production of ADHD medications to the Asian region. Companies gain product portfolio augmentation through mergers and acquisition activities.

Moreover, companies are engaging in mergers and acquisitions to increase their product offerings and global market presence.

Some key instances of development include:

• Japan granted approval for the use of UCB's Vimpat® (lacosamide) in January 2019 to treat partial-onset seizures in children aged 4 and older.
• Pfizer Inc. purchased Array, a biopharmaceutical firm specialising in the discovery and marketing of small molecule drugs, in July 2019.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the attention deficit hyperactivity disorder therapeutics market, which are available in the full report.

Attention Deficit Hyperactivity Disorder Therapeutics Industry Report Scope

Key Segments Covered in Attention Deficit Hyperactivity Disorder Therapeutics Industry Research

Drug:

• Stimulants
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
• Non-stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine

Age Group:

• Pediatric and Adolescent
• Adults

Distribution Channel:

• Specialty Clinics
• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

To know more about delivery timeline for this report Contact Sales